Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors
US10231969B2 · kind B2 · utility
7Cited by
28References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2017 |
| Grant date | Mar 19, 2019 |
| Priority date | — |
| Expiry date | Mar 13, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.